Cytek Biosciences, Inc. CTKB
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 53.23M | 48.14M | 44.14M | 62.14M | 52.29M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 53.23M | 48.14M | 44.14M | 62.14M | 52.29M |
| Cost of Revenue | 22.02M | 22.60M | 22.88M | 29.26M | 24.74M |
| Gross Profit | 31.21M | 25.54M | 21.25M | 32.89M | 27.55M |
| SG&A Expenses | 30.27M | 30.00M | 30.11M | 29.52M | 27.79M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 61.65M | 62.34M | 62.60M | 67.74M | 61.49M |
| Operating Income | -8.42M | -14.20M | -18.46M | -5.59M | -9.19M |
| Income Before Tax | -6.91M | -11.64M | -17.37M | -4.03M | -7.77M |
| Income Tax Expenses | -811.00K | 515.00K | 1.49M | 40.05M | -2.29M |
| Earnings from Continuing Operations | -6.10M | -12.16M | -18.87M | -44.08M | -5.48M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -6.10M | -12.16M | -18.87M | -44.08M | -5.48M |
| EBIT | -8.42M | -14.20M | -18.46M | -5.59M | -9.19M |
| EBITDA | -6.31M | -12.19M | -16.60M | -3.70M | -7.27M |
| EPS Basic | -0.05 | -0.09 | -0.15 | -0.34 | -0.04 |
| Normalized Basic EPS | -0.03 | -0.06 | -0.08 | -0.02 | -0.04 |
| EPS Diluted | -0.05 | -0.09 | -0.15 | -0.34 | -0.04 |
| Normalized Diluted EPS | -0.03 | -0.06 | -0.08 | -0.02 | -0.04 |
| Average Basic Shares Outstanding | 130.36M | 129.46M | 128.70M | 128.17M | 127.55M |
| Average Diluted Shares Outstanding | 130.36M | 129.46M | 128.70M | 128.17M | 127.55M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |